Chiao-Wei Lo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chiao-Wei Lo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chia-Feng Yang
Department of Pediatrics Taipei Veterans General Hospital Taipei Taiwan
1 shared publication - Chun-Kai Huang
Department of Pediatrics, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan
1 shared publication - Dau-Ming Niu
Institute of Clinical Medicine, National Yang Ming Chiao Tung University
1 shared publication - Fu-Pang Chang
Pathology and Laboratory Medicine Department, Taipei Veterans General Hospital, Taipei, Taiwan
1 shared publication - Hao-Chuan Liu
Department of Pediatrics, Taipei Veterans General Hospital, No. 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan
1 shared publication - Hsiang-Yu Lin
Department of Pediatrics, Mackay Memorial Hospital, Taipei 104217, Taiwan
1 shared publication
Latest Publications
- Open Access
- 22 July 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 111
Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)
In Taiwan, DNA-based newborn screening showed a surprisingly high incidence (1/875 in males and 1/399 in females) of a cardiac Fabry mutation (IVS4 + 919G > A). However, the natural course, long-term treatment outcomes and suitable biomarkers for monitoring the therapeutic outcomes of these patients are largely unknown.
- 22 July 2014
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 9 (1) , 111
Open AccessGlobotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)
In Taiwan, DNA-based newborn screening showed a surprisingly high incidence (1/875 in males and 1/399 in females) of a cardiac Fabry mutation (IVS4 + 919G > A). However, the natural course, long-term treatment outcomes and suitable biomarkers for monitoring the therapeutic outcomes of these patients are largely unknown.